Prot# CRAD001L2202: An Open-Label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-Line Followed by Second-Line Sunitinib versus Sunitinib as First-Line Followed by Second-Line RAD001 in the Treatment of Patients with Met

  • Kuzel, Timothy Michael (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date7/28/092/20/13

Funding

  • Novartis Pharmaceuticals Corporation (Prot# CRAD001L2202)